Global pharmaceutical company Almirall has announced it will launch three clinical trials in 2026 to further advances in the medical dermatology field. 

Speaking at the 44th J.P. Morgan Healthcare Conference, which took place in San Francisco, Almirall CEO Carlos Gallardo said the company was focused on developing impactful novel treatments for high unmet medical need skin diseases using a variety of different technology approaches. 

Almirall is currently supporting three ongoing proof-of-concept (PoC)/Phase II trials. This includes a study into an anti-IL-1RAP monoclonal antibody (mAb) targeting hidradenitis suppurativa, an IL-2muFc mutant fusion protein targeting alopecia areata and targeting atopic dermatitis. 

The company is set to launch three additional PoC clinical studies in 2026. Plans include studies into an anti-IL-21 mAb targeting hidradenitis suppurativa and one additional inflammatory skin disease for the anti-IL-1RAP and the IL-2muFc mutant fusion protein, respectively. Almirall also plans to advance a bispecific antibody targeting both IL-13 and OX-40L for the treatment of atopic dermatitis into Phase I in the first half of 2026. 

“We are excited about the opportunities our broad R&D pipeline offers – to patients, the medical community, and for the future growth of Almirall,” said Carlos Gallardo, CEO and President of Almirall. 

“In addition to the three ongoing Proof-of-Concept studies we are planning to initiate another three this year which makes this a first in Almirall’s long history and is testament to our dedication to medical dermatology.  

“Progressing a number of promising assets to address high impact skin diseases is made possible by the sustained previous investments we have made into commercial excellence for the launch of breakthrough assets, as well as our expertise, scientific capabilities, and infrastructure which are key factors for our leadership in medical dermatology.” 

Almirall’s pledged investment into dermatologic studies comes as the company predicts double-digit net sales by 2030.   

 

Bruno Quinney, Content Team, DDW